Abstract
Disorders of the central nervous system (CNS) are some of the most prevalent, devastating and yet poorly treated illnesses. The development of new therapies for CNS disorders such as Alzheimer's disease has the potential to provide patients with significant improvements in quality of life, as well as reduce the future economic burden on health-care systems. However, few truly innovative CNS drugs have been approved in recent years, suggesting that there is a considerable need for strategies to enhance the productivity of research and development in this field. In this article, using illustrative examples from neurological and psychiatric disorders, we describe various approaches that are being taken to discover CNS drugs, discuss their relative merits and consider how risk can be balanced and attrition reduced.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Pharmaceutical Research and Manufacturers of America (PhRMA). New Medicines in Development for Mental Illness. PhRMA web site [online], (2006).
Pharmaceutical Research and Manufacturers of America (PhRMA). New Medicines in Development for Neurological Disorders. PhRMA web site [online], (2006).
Ferri, C. P. et al. Global prevalence of dementia: a Delphi consensus study. Lancet 366, 2112–2117 (2005).
Kola, I. & Landis, J. Can the pharmaceutical industry reduce attrition rates? Nature Rev. Drug Discov. 3, 711–715 (2004).
Tufts Center for the Study of Drug Development. Longer clinical times are extending time to market for new drugs in US. Tufts CSDD Impact Report 7, 1–4 (2005).
Bornstein, N., Silvestrelli, G., Caso, V. & Parnetti, L. Arterial hypertension and stroke prevention: an update. Clin. Exp. Hypertens. 28, 317–326 (2006).
Sato, A., Saruta, T. & Funder J. W. Combination therapy with aldosterone blockade and renin-angiotensin inhibitors confers organ protection. Hypertens. Res. 29, 211–216 (2006).
Nitsch, R. M., Slack, B. E., Wurtman, R. J. & Growdon, J. H. Release of Alzheimer amyloid precursor derivatives stimulated by activation of muscarinic acetylcholine receptors. Science 258, 304–307 (1992).
Pangalos, M. N., Jacobsen, S. J. & Reinhart, P. H. Disease modifying strategies for the treatment of Alzheimer's disease targeted at modulating levels of the β-amyloid peptide. Biochem. Soc. Trans. 33, 553–558 (2005).
Dominguez, D. I. & De Strooper, B. Novel therapeutic strategies provide the real test for the amyloid hypothesis of Alzheimer's disease. Trends Pharmacol. Sci. 23, 324–330 (2002).
Zhang, L. et al. Characterization of the reconstituted γ-secretase complex from Sf9 cells co-expressing presenilin 1, nicastrin, aph-1a, and pen-2. Biochemistry 44, 4450–4457 (2005).
Marambaud, P. et al. A presenilin-1/γ-secretase cleavage releases the E-cadherin intracellular domain and regulates disassembly of adherens junctions. EMBO J. 21, 1948–1956 (2002).
Roberds, S. L. et al. BACE knockout mice are healthy despite lacking the primary β-secretase activity in brain: implications for Alzheimer's disease therapeutics. Hum. Mol. Genet. 10, 1317–1324 (2001).
Hong, L. et al. Crystal structure of memapsin 2 (β-secretase) in complex with an inhibitor OM00–3. Biochemistry 41, 10963–10967 (2002).
Booth, B. & Zemmel, R. Prospects for productivity. Nature Rev. Drug Discov. 3, 451–456 (2004).
Hornig, C. R. et al. CT contrast enhancement on brain scans and blood–CSF barrier disturbances in cerebral ischemic infarction. Stroke 16, 268–273 (1985).
Papadopoulos, C. M. et al. Dendritic plasticity in the adult rat following middle cerebral artery occlusion and Nogo-a neutralization. Cereb. Cortex 16, 529–536 (2006).
Schenk, D. et al. Immunization with amyloid-β attenuates Alzheimer-disease-like pathology in the PDAPP mouse. Nature 400, 173–177 (1999).
Bard, F. et al. Peripherally administered antibodies against amyloid β-peptide enter the central nervous system and reduce pathology in a mouse model of Alzheimer disease. Nature Med. 6, 916–919 (2000).
Braak, H. & Braak, E. Neuropathological stageing of Alzheimer-related changes. Acta Neuropathol. (Berl.) 82, 239–259 (1991).
Akiyama, H. et al. Inflammation and Alzheimer's disease. Neurobiol. Aging 21, 383–421 (2000).
Reddy, P. & Beal, M. Are mitochondria critical in the pathogenesis of Alzheimer's disease? Brain Res. Brain Res. Rev. 49, 618–632 (2005).
Kivipelto, M. et al. Apolipoprotein E ɛ4 allele, elevated midlife total cholesterol level, and high midlife systolic blood pressure are independent risk factors for late-life Alzheimer disease. Ann. Intern. Med. 137, 149–155 (2002).
Brunton, V. G. et al. Identification of Src-specific phosphorylation site on focal adhesion kinase: dissection of the role of Src SH2 and catalytic functions and their consequences for tumor cell behavior. Cancer Res. 65, 1335–1342 (2005).
Paul, R. et al. Src deficiency or blockade of Src activity in mice provides cerebral protection following stroke. Nature Med. 7, 222–227 (2001).
Lebovitz, H. Diabetes: assessing the pipeline. Atheroscler. Suppl. 7, 43–49 (2006).
Feinstein, D. L. et al. Peroxisome proliferator-activated receptor-γ agonists prevent experimental autoimmune encephalomyelitis. Ann. Neurol. 51, 694–702 (2002).
Heneka, M. T., Landreth, G. E. & Feinstein, D. L. Role for peroxisome proliferator-activated receptor-γ in Alzheimer's disease. Ann. Neurol. 49, 276 (2001).
Rosenzweig-Lipson, S. et al. Antiobesity-like effects of the 5-HT2C receptor agonist WAY-161503. Brain Res. 1073–1074, 240–251 (2006).
Schechter, L. et al. Innovative approaches for the development of antidepressant drugs: current and future strategies. NeuroRx 2, 590–611 (2005).
Porter R. H. et al. A clinically validated nonbenzodiazepine anxiolytic is a potent, selective, and noncompetitive mGlu5 receptor antagonist with inverse agonist activity. J. Pharmacol. Exp. Ther. 315, 711–721 (2005).
Miyamoto, S., Duncan, G. E., Marx, C. E. & Lieberman, J. A. Treatments for schizophrenia: a critical review of pharmacology and mechanisms of action of antipsychotic drugs. Mol. Psychiatry 10, 79–104 (2005).
Braff, D. L. L., G. A. . The use of neurophysiological endophenotypes to understand the genetic basis of schizophrenia. Dialogues Clin. Neurosci. 7, 125–135 (2005).
Recommendations for standards regarding preclinical neuroprotective and restorative drug development. Stroke 30, 2752–2758 (1999).
Lees, K. R. et al. NXY-059 for acute ischemic stroke. N. Engl. J. Med. 354, 588–600 (2006).
Ireland, R. Is NXY-059 beneficial in ischemic stroke? Nature Clin. Pract. Cardiovasc. Med. 3, 240–241 (2006).
Fong, J. J. & Rhoney, D. H. NXY-059: review of neuroprotective potential for acute stroke. Ann. Pharmacother. 40, 461–471 (2006).
[No Authors Listed]. The Bitterest pill. Nature 444, 532–533 (2006).
Leow, A. D. et al. Longitudinal stability of MRI for mapping brain change using tensor-based morphometry. Neuroimage 31, 627–640 (2006).
Schenk, D., Games, K. D. & McConlogue, L. The potential utility of transgenic mice harboring β-amyloid precursor protein. Neurobiol. Aging 16, 711–713 (1995).
Bloom, F. E. et al. Mouse models of human neurodegenerative disorders: requirements for medication development. Arch. Neurol. 62, 185–187 (2005).
Harrison, S. M. et al. BACE1 (β-secretase) transgenic and knockout mice: identification of neurochemical deficits and behavioral changes. Mol. Cell. Neurosci. 24, 646–55 (2003).
Laird, F. M. et al. BACE1, a major determinant of selective vulnerability of the brain to amyloid-β amyloidogenesis, is essential for cognitive, emotional, and synaptic functions. J. Neurosci. 25, 11693–11709 (2005).
Roher, A. E. & Kokjohn, T. A. Appraisal of AβPP transgenic mice as models for Alzheimer's disease amyloid cascade. Curr. Med. Chem. 3, 85–90 (2003).
Lehmann, H. E. & Ban, T. A. The history of the psychopharmacology of schizophrenia. Can. J. Psychiatry 42, 152–162 (1997).
Janssen, P. A., Niemegeers, C. J. & Schellekens, K. H. Is it possible to predict the clinical effects of neuroleptic drugs (major tranquillizers) from animal data?I. 'Neuroleptic Activity Spectra' for rats. Arzneimittelforschung. 15, 104–117 (1965).
Costall, B., Naylor, R. J. & Nohria, V. Climbing behaviour induced by apomorphine in mice: a potential model for the detection of neuroleptic activity. Eur. J. Pharmacol. 50, 39–50 (1978).
Braff, D. L. & Geyer, M. A. Sensorimotor gating and schizophrenia. Human and animal model studies. Arch. Gen. Psychiatry 47, 181–188 (1990).
Lipska, B. & Weinberger, D. To model a psychiatric disorder in animals: schizophrenia as a reality test. Neuropsychopharmacology 23, 223–239 (2000).
Cryan, J., Markou, A. & Lucki, I. Assessing antidepressant activity in rodents: recent developments and future needs. Trends Pharmacol. Sci. 23, 238–245 (2002).
Rupniak, N. M. & Kramer, M. S. Discovery of the antidepressant and anti-emetic efficacy of substance P receptor (NK1) antagonists. Trends Pharmacol. Sci. 20, 485–490 (1999).
Herpfer, I. & Lieb, K. Substance P receptor antagonists in psychiatry: rationale for development and therapeutic potential. CNS Drugs 19, 275–293 (2005).
Ranga, K. & Krishnan, R. Clinical experience with substance P receptor (NK1) antagonists in depression. J. Clin. Psychiatry. 63 (Suppl. 11), 25–29 (2002).
Frank, R. & Hargreaves, R. Clinical biomarkers in drug discovery and development. Nature Rev. Drug Discov. 2, 566–280 (2003).
Nestler, E. et al. Preclinical models: Status of basic research in depression. Biol. Psychiatry 52, 503–528 (2002).
Risch, N. & Botstein, D. A manic depressive history. Nature Genet. 12, 351–353 (1996).
Terwilliger, J. On the resolution and feasibility of genome scanning approaches. Adv. Genet. 42, 351–391 (2001).
Harrison, P. & Weinberger, D. Schizophrenia genes, gene expression, and neuropathology: on the matter of their convergence. Mol. Psychiatry 10, 40–68 (2005).
Kamiya, A. et al. A schizophrenia-associated mutation of DISC1 perturbs cerebral cortex: development. Nature Cell Biol. 7, 1167–1178 (2005).
Rawlins, M. D. Cutting the cost of drug development? Nature Rev. Drug Discov. 3, 360–364 (2004).
Sheiner, L. Learning versus confirming in clinical drug development. Clin. Pharm. Ther. 61, 275–291 (1997).
Whalley, L., Deary, I., Appleton, C. & Starr, J. Cognitive reserve and the neurobiology of cognitive aging. Ageing Res. Rev. 3, 369–382 (2004).
Winblad, B. & Poritis, N. Memantine in severe dementia: results of the 9M-Best Study (Benefit and efficacy in severely demented patients during treatment with memantine). Int. J. Geriatr. Psychiatry 14, 135–146 (1999).
Rush, A. J. et al. Bupropion-SR, sertraline, or venlafaxine-XR after failure of SSRIs for depression. N. Engl. J. Med. 354, 1231–1242 (2006).
Trivedi, M. H. et al. Medication augmentation after the failure of SSRIs for depression. N. Engl. J. Med. 354, 1243–1252 (2006).
Wolf, C. R. & Smith, G. Cytochrome P450 CYP2D6. IARC Sci. Publ. 148, 209–229 (1999).
Emilien, G., Ponchon, M., Caldas, C., Isacson, O. & Maloteaux, J. M. Impact of genomics on drug discovery and clinical medicine. Q. J. Med. 93, 391–423 (2000).
Poulsen, L. et al. Codeine and morphine in extensive and poor metabolizers of sparteine: pharmacokinetics, analgesic effect and side effects. Eur. J. Clin. Pharmacol. 51, 289–295 (1996).
Defilippi, J. L. & Crismon, M. L. Drug interactions with cholinesterase inhibitors. Drugs Aging 20, 437–444 (2003).
Smeraldi, E. et al. Polymorphism within the promoter of the serotonin transporter gene and antidepressant efficacy of fluvoxamine. Mol. Psychiatry 3, 508–511 (1998).
Lane, H. Y. et al. Association of risperidone treatment response with a polymorphism in the 5-HT(2A) receptor gene. Am. J. Psychiatry 159, 1593–1595 (2002).
Roses, A. D. et al. Complex disease-associated pharmacogenetics: drug efficacy, drug safety, and confirmation of a pathogenetic hypothesis (Alzheimer's disease). Pharmacogenomics J. 7, 10–28 (2007).
Tsuang, M. T. & Faraone, S. V. Genetics of Alzheimer's disease. J. Formos. Med. Assoc. 95, 733–740 (1996).
Klimas, M. Positron emission tomography and drug discovery: contributions to the understanding of pharmacokinetics, mechanism of action and disease state characterization. Mol. Imaging Biol. 4, 311–337 (2002).
Dawson, D. A., Wadsworth, G. & Palmer, A. M. A comparative assessment of the efficacy and side-effect liability of neuroprotective compounds in experimental stroke. Brain Res. 892, 344–350 (2001).
Matsuoka, Y. et al. An Aβ sequestration approach using non-antibody Aβ binding agents. Curr. Alzheimer Res. 2, 265–268 (2005).
Kayed, R. et al. Common structure of soluble amyloid oligomers implies common mechanism of pathogenesis. Science 300, 486–489 (2003).
Motter, R. et al. Reduction of β-amyloid peptide42 in the cerebrospinal fluid of patients with Alzheimer's disease. Ann. Neurol. 38, 643–648 (1995).
Lewczuk, P. et al. Tau protein phosphorylated at threonine 181 in CSF as a neurochemical biomarker in Alzheimer's disease: Original data and review of the literature. J. Mol. Neurosci. 23, 115–122 (2004).
Pratico, D. & Sung, S. Lipid peroxidation and oxidative imbalance: early functional events in Alzheimer's disease. J. Alzheimers Dis. 6, 171–175 (2004).
Renna, M., Handy, J. & Shah, A. Low baseline Bispectral Index of the electroencephalogram in patients with dementia. Anesth. Analg. 96, 1380–1385 (2003).
LeBlanc, J., Dasta, J. & Kane-Gill, S. Role of the bispectral index in sedation monitoring in the ICU. Ann. Pharmacother. 40, 490–500 (2006).
Herrmann, C. & Demiralp, T. Human EEG γ oscillations in neuropsychiatric disorders. Clin. Neurophysiol. 116, 2719–2733 (2005).
Mohs, R. et al. Development of cognitive instruments for use in clinical trials of antidementia drugs: additions to the Alzheimer's Disease Assessment Scale that broaden its scope. The Alzheimer's Disease Cooperative Study. Alzheimer Dis. Assoc. Disord. 11 (Suppl. 2), 13–21 (1997).
Solomon, P. et al. Classical conditioning in patients with Alzheimer's disease: a multiday study. Psychol. Aging 10, 248–254 (1995).
Skelton, R., Ross, S., Nerad, L. & Livingstone, S. Human spatial navigation deficits after traumatic brain injury shown in the arena maze, a virtual Morris water maze. Brain Inj. 20, 189–203 (2006).
Pariente, J. et al. Alzheimer's patients engage an alternative network during a memory task. Ann Neurol 58, 870–879 (2005).
Frank, R. A. et al. Biological markers for therapeutic trials in Alzheimer's disease. Proceedings of the biological markers working group; NIA initiative on neuroimaging in Alzheimer's disease. Neurobiol. Aging 24, 521–536 (2003).
Klunk, W. et al. Binding of the positron emission tomography tracer Pittsburgh compound-B reflects the amount of amyloid-β in Alzheimer's disease brain but not in transgenic mouse brain. J. Neurosci. 25, 10598–10606 (2005).
Kung, M., Zhuang, Z., Hou, C. & Kung, H. Development and evaluation of iodinated tracers targeting amyloid plaques for SPECT imaging. J. Mol. Neurosci. 24, 49–53 (2004).
Versijpt, J. et al. Assessment of neuroinflammation and microglial activation in Alzheimer's disease with radiolabelled PK11195 and single photon emission computed tomography. A pilot study. Eur. Neurol. 50, 39–47 (2003).
Johnson, N. et al. Pattern of cerebral hypoperfusion in Alzheimer disease and mild cognitive impairment measured with arterial spin-labeling MR imaging: initial experience. Radiology 234, 851–859 (2005).
Han, S., Nestor, P. & Wible, C. fMRI of lexical-semantic priming in a chronic schizophrenia patient. Appl. Neuropsychol. 13, 51–57 (2006).
Chudasama, Y. & Robbins, T. W. Dopaminergic modulation of visual attention and working memory in the rodent prefrontal cortex. Neuropsychopharmacology 29, 1628–1636 (2004).
Spinelli, S. et al. Performance of the marmoset monkey on computerized tasks of attention and working memory. Brain Res. Cogn. Brain Res. 19, 123–137 (2004).
Spinelli, S. et al. Effects of the mGluR2/3 agonist LY354740 on computerized tasks of attention and working memory in marmoset monkeys. Psychopharmacology (Berl.) 179, 292–302 (2005).
Olson, H. et al. Concordance of the toxicity of pharmaceuticals in humans and in animals. Regul. Toxicol. Pharmacol. 32, 56–67 (2000).
Huby, R. & Tugwood, J. D. Gene expression profiling for pharmaceutical safety assessment. Expert Opin. Drug Metab. Toxicol. 1, 247–260 (2005).
Drazen, J. M. Patients at risk. N. Engl. J. Med. 353, 417 (2005).
O'Toole, M. et al. Risk factors associated with β-amyloid(1–42) immunotherapy in preimmunization gene expression patterns of blood cells. Arch. Neurol. 62, 1531–1536 (2005).
Davies, P. & Maloney, A. J. Selective loss of central cholinergic neurons in Alzheimer's disease. Lancet 2, 1403 (1976).
Bowen, D. M., Smith, C. B., White, P. & Davison, A. N. Neurotransmitter-related enzymes and indices of hypoxia in senile dementia and other abiotrophies. Brain 99, 459–496 (1976).
Perry, E. K., Perry, R. H., Blessed, G. & Tomlinson, B. E. Necropsy evidence of central cholinergic deficits in senile dementia. Lancet 1, 189 (1977).
Whitehouse, P. J. et al. Alzheimer's disease and senile dementia: loss of neurons in the basal forebrain. Science 215, 1237–1239 (1982).
Bartus, R. T., Dean, R. L. 3rd, Beer, B. & Lippa, A. S. The cholinergic hypothesis of geriatric memory dysfunction. Science 217, 408–414 (1982).
Ferrante, R. J., Kowall, N. W. & Richardson, E. P. Jr . Proliferative and degenerative changes in striatal spiny neurons in Huntington's disease: a combined study using the section-Golgi method and calbindin D28k immunocytochemistry. J. Neurosci. 11, 3877–3887 (1991).
Francis, P. T. et al. Antemortem measurements of neurotransmission: possible implications for pharmacotherapy of Alzheimer's disease and depression. J. Neurol. Neurosurg. Psychiatry 56, 80–84 (1993).
Schechter, L. et al. Lecozotan (SRA-333): A selective serotonin 1A receptor antagonist that enhances the stimulated release of glutamate and acetylcholine in the hippocampus and possesses cognitive-enhancing properties. J. Pharmacol. Exp. Ther. 314, 1274–1289 (2005).
King, M. V. et al. 5-HT6 receptor antagonists reverse delay-dependent deficits in novel object discrimination by enhancing consolidation — an effect sensitive to NMDA receptor antagonism. Neuropharmacology 47, 195–204 (2004).
Komater, V. A. et al. H3 receptor blockade by thioperamide enhances cognition in rats without inducing locomotor sensitization. Psychopharmacology (Berl.) 167, 363–372 (2003).
Selkoe, D. J. & Schenk, D. Alzheimer's disease: molecular understanding predicts amyloid-based therapeutics. Annu. Rev. Pharmacol. Toxicol. 43, 545–584 (2003).
St George-Hyslop, P. H. & Petit, A. Molecular biology and genetics of Alzheimer's disease. C. R. Biol. 328, 119–130 (2005).
Podlisny, M. B., Lee, G. & Selkoe, D. J. Gene dosage of the amyloid β precursor protein in Alzheimer's disease. Science 238, 669–671 (1987).
DeMattos, R. B. et al. ApoE and clusterin cooperatively suppress Aβ levels and deposition. Evidence that ApoE regulates extracellular Aβ metabolism in vivo. Neuron 41, 193–202 (2004).
Klein, W. L. Aβ toxicity in Alzheimer's disease: globular oligomers (ADDLs) as new vaccine and drug targets. Neurochem. Int. 41, 345–352 (2002).
Lesne, S. et al. A specific amyloid-β protein assembly in the brain impairs memory. Nature 440, 352–357 (2006).
Walsh, D. M. et al. Naturally secreted oligomers of amyloid β protein potently inhibit hippocampal long-term potentiation in vivo. Nature 416, 535–539 (2002).
Jacobsen, J. S., Reinhart, P. & Pangalos, M. N. Current concepts in therapeutic strategies targeting cognitive decline and disease modification in Alzheimer's disease. NeuroRx 2, 612–626 (2005).
Carlsson, A., Jonason, J., Lindqvist, M. & Fuxe, K. Demonstration of extraneuronal 5-hydroxytryptamine accumulation in brain following membrane-pump blockade by chlorimipramine. Brain Res. 2, 456–460 (1969).
Goodwin, F. & Bunney, W. J. Depressions following reserpine: A reevaluation. Semin. Psychiatry 3, 435–448 (1971).
Hirschfeld, R. History and evolution of the monoamine hypothesis of depression. J. Clin. Psychiatry 61, 4–6 (2000).
Artigas, F., Romero, L., de Montigny, C. & Blier, P. Acceleration of the effect of selected antidepressant drugs in major depression by 5-HT1A antagonists. Trends Neurosci. 19, 378–383 (1996).
Merikangas, K. & Risch, N. Will the genomics revolution revolutionize psychiatry? Am. J. Psychiatry 160, 625–635 (2003).
Hasler, G., Drevets, W., Manji, H. & Charney, D. Discovering endophenotypes for major depression. Neuropsychopharmacology 29, 1765–1781 (2004).
Kinney, D. et al. Season of birth and obstetrical complications in schizophrenics. J. Psychiatr. Res. 28, 499–509 (1994).
Kelly, B., Lane, A., Agartz, I., Henriksson, K. & McNeil, T. Craniofacial dysmorphology in Swedish schizophrenia patients. Acta Psychiatr. Scand. 111, 202–207 (2005).
Sheline, Y., Gado, M. & Kraemer, H. Untreated depression and hippocampal volume loss. Am. J Psychiatry 160, 1516–1518 (2003).
Sheline, Y., Wang, P., Gado, M., Csernansky, J. & Vannier, M. Hippocampal atrophy in recurrent major depression. Proc. Natl Acad. Sci. USA 93, 3908–3913 (1996).
Malberg, J., Eisch, A., Nestler, E. & Duman, R. Chronic antidepressant treatment increases neurogenesis in adult rat hippocampus. J. Neurosci. 20, 9104–9110 (2000).
Acknowledgements
We would like to thank K. Charles, G. Burr and M. Glick for thoughtful comments and review of the manuscript. N. Bryan for providing help with the images in figure 2. We would also like to thank M. Weiner, University of California, San Francisco, as well as B. Miller, N. Schuff and D. Antao for providing the images in figure 3.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
All authors are employees of Wyeth Pharmaceuticals and own shares and company stock options.
Related links
Related links
DATABASES
OMIM
FURTHER INFORMATION
Alzheimer's Disease Neuroimaging Initiative
Treatment Units for Research on Neurocognition and Schizophrenia
Rights and permissions
About this article
Cite this article
Pangalos, M., Schechter, L. & Hurko, O. Drug development for CNS disorders: strategies for balancing risk and reducing attrition. Nat Rev Drug Discov 6, 521–532 (2007). https://doi.org/10.1038/nrd2094
Issue Date:
DOI: https://doi.org/10.1038/nrd2094
This article is cited by
-
VHHs as tools for therapeutic protein delivery to the central nervous system
Fluids and Barriers of the CNS (2022)
-
Vesicle trafficking and pathways to neurodegeneration
Molecular Neurodegeneration (2021)
-
Mismatch negativity as EEG biomarker supporting CNS drug development: a transnosographic and translational study
Translational Psychiatry (2021)
-
Trends in peptide drug discovery
Nature Reviews Drug Discovery (2021)